Literature DB >> 6748162

Isolation of vaccinia virus mutants capable of replicating independently of the host cell nucleus.

E C Villarreal, N A Roseman, D E Hruby.   

Abstract

alpha-Amanitin-resistant vaccinia virus mutants were isolated after serial viral passages in BSC-40 cells that were carried out in the presence of inhibitory levels (6 micrograms/ml) of alpha-amanitin. One such mutant, alpha-27, was highly refractory (greater than 95%) to alpha-amanitin-mediated inhibition and was selected for further study. In the absence of drug, the phenotypes of alpha-27 and wild-type vaccinia virus were indistinguishable with respect to growth kinetics. DNA synthesis, protein synthesis, and morphogenesis. Infections in the presence of alpha-amanitin revealed two striking differences, however. First, wild-type virus was unable to catalyze proteolytic processing of the two major capsid proteins VP62 and VP60, whereas alpha-27 was most efficient at this process. Second, wild-type viral morphogenesis within the infected cells was arrested by alpha-amanitin at an apparently analogous step to that previously described for enucleated cells. This observation was supported by the ability of alpha-27 virus to replicate in enucleated BSC-40 cells. Restriction enzyme analyses of alpha-27 versus wild-type genomes revealed that a XhoI cleavage site was altered in the alpha-27 DNA molecule, suggesting a possible location for the alpha-amanitin resistance locus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6748162      PMCID: PMC254446          DOI: 10.1128/JVI.51.2.359-366.1984

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Biogenesis of poxviruses: role for the DNA-dependent RNA polymerase II of the host during expression of late functions.

Authors:  M Silver; G McFadden; S Wilton; S Dales
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

2.  Virus development in enucleate cells: echovirus, poliovirus, pseudorabies virus, reovirus, respiratory syncytial virus and Semliki Forest virus.

Authors:  E A Follett; C R Pringle; T H Pennington
Journal:  J Gen Virol       Date:  1975-02       Impact factor: 3.891

3.  Vaccinia virus infection of HeLa cells. II. Disparity between cytoplasmic and nuclear viral-specific RNA.

Authors:  A Bolden; G P Noy; A Weissbach
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

4.  Analysis of bacteriophage T7 early RNAs and proteins on slab gels.

Authors:  F W Studier
Journal:  J Mol Biol       Date:  1973-09-15       Impact factor: 5.469

5.  Rifampicin: a specific inhibitor of vaccinia virus assembly.

Authors:  B Moss; E N Rosenblum; E Katz; P M Grimley
Journal:  Nature       Date:  1969-12-27       Impact factor: 49.962

6.  Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

7.  Vaccinia virus replication. I. Requirement for the host-cell nucleus.

Authors:  D E Hruby; L A Guarino; J R Kates
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

8.  Vaccinia virus replication requires active participation of the host cell transcriptional apparatus.

Authors:  D E Hruby; D L Lynn; J R Kates
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

9.  Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin.

Authors:  E Katz; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1970-07       Impact factor: 11.205

10.  Vaccinia virus replication in enucleate BSC-1 cells: particle production and synthesis of viral DNA and proteins.

Authors:  T H Pennington; E A Follett
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

View more
  10 in total

1.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  DNA sequences that regulate expression of a vaccinia virus late gene (L65) and interact with a DNA-binding protein from infected cells.

Authors:  J N Miner; D E Hruby
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.

Authors:  S K Poddar; W R Bauer
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

4.  Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells.

Authors:  A M DeLange; G McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

5.  Suppressors of a host range mutation in the rabbitpox virus serpin SPI-1 map to proteins essential for viral DNA replication.

Authors:  Benjamin G Luttge; Richard W Moyer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Identification of temperature-sensitive mutants of vaccinia virus that are defective in conversion of concatemeric replicative intermediates to the mature linear DNA genome.

Authors:  A M DeLange
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

7.  Intramolecular homologous recombination in cells infected with temperature-sensitive mutants of vaccinia virus.

Authors:  M Merchlinsky
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Mapping the genomic location of the gene encoding alpha-amanitin resistance in vaccinia virus mutants.

Authors:  E C Villarreal; D E Hruby
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase.

Authors:  M B Slabaugh; C K Mathews
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

10.  A cellular factor is required for transcription of vaccinia viral intermediate-stage genes.

Authors:  R Rosales; G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.